Withdrawal of 500/mg roflumilast after 12 weeks of treatment versus continued treatment for 24 weeks versus placebo in patients with chronic obstructive pulmonary disease

*Please Note* The Study you are attempting to view was acquired from Takeda by AstraZeneca and was disclosed initially by Takeda per their Transparency Policies. More information regarding this study may be available by contacting [email protected].

A phase 3, double-blind, randomized, parallel-group, placebo-controlled study with a single-blind baseline period in subjects with chronic obstructive pulmonary disease (COPD).